dc.contributor | Departament de Salut |
dc.contributor.author | Programa d'Harmonització Farmacoterapèutica |
dc.date.accessioned | 2019-06-12T10:13:52Z |
dc.date.available | 2019-06-12T10:13:52Z |
dc.date.issued | 2019-02-01 |
dc.identifier.citation | Programa d'Harmonització Farmacoterapèutica. Ibrutinib per al tractament de la leucèmia limfocítica crònica. Barcelona: Servei Català de la Salut; 2019. |
dc.identifier.uri | https://hdl.handle.net/11351/4131 |
dc.description | Ibrutinib; Monotherapy; Chronic lymphocytic leukemia |
dc.description.abstract | Chronic lymphocytic leukemia (LLC) is the most frequent type of leukemia in adults in the western world, representing 25-50% of all leukemia. The median age at diagnosis is 72 years and only 10% of patients are <55 years. It has a prevalence of 3.5 cases / 10,000 inhabitants and an annual incidence of 5 new cases / 100,000 inhabitants. The incidence increases to> 30 cases / 100,000 / year in patients> 70 years. It affects more frequently men than women (2: 1) |
dc.language.iso | cat |
dc.publisher | Servei Català de la Salut |
dc.relation.ispartof | Programa d'Harmonització Farmacoterapèutica, Servei Català de la Salut |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Leucèmia limfocítica crònica - Tractament |
dc.subject | Medicaments - Assaigs clínics |
dc.subject.mesh | Leukemia, Lymphocytic, Chronic, B-Cell |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Drug Evaluation |
dc.title | Ibrutinib per al tractament de la leucèmia limfocítica crònica |
dc.type | info:eu-repo/semantics/report |
dc.subject.decs | leucemia linfocítica crónica de células B |
dc.subject.decs | /tratamiento farmacológico |
dc.subject.decs | evaluación de medicamentos |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |